Use of agents stimulating erythropoiesis in digestive diseases  

作　　者：Rosario Moreno López Beatriz Sicilia Aladrén Fernando Gomollón García 

机构地区：[1]Department of Nephrology, San Juan de Dios Hospital, Paseo Colón, 14, 50006 Zaragoza, Spain [2]Department of Medicine, Universidad de Zaragoza, 50009 Zaragoza, Spain [3]Department of Medicine (Gastroenterology), Alcaiz Hospital, 44600 Alcaiz (Teruel), Spain [4]Department of Gastroenterology, Clinical University Hospital "Lozano Blesa", Department of Medicine, University of Zaragoza, IACS, CIBEREHD, 50009 Zaragoza, Spain

出　　处：《World Journal of Gastroenterology》2009年第37期4675-4685,共11页世界胃肠病学杂志（英文版）

摘　　要：Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron def iciency in IBD. There is also a variable component of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin (rHuEPO), which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as f irst choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit (11-12 g/dL). New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same eff icacy and safety.Anemia is the most common complication of inflammatory bowel disease （IBD）. Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron deficiency in IBD. There is also a variable compo- nent of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin （rHuEPO）, which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as first choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit （11-12 g/dL）. New formulations of intravenous iron （iron carboxymaltose） and the new generation of erythropoietic agents （darbepoetin and continuous erythropoietin receptor activator） will allow better dosing with the same efficacy and safety.

关 键 词：Erythropoiesis-stimulating agents Recom-binant human erythropoietin DARBEPOETIN Continuous erythropoietin receptor activator Inflammatory bowel disease ANEMIA 

分 类 号：R57[医药卫生—消化系统]